Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced afterload.
Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.
Short-term treatment of hypertension when oral therapy is not feasible or desirable
Treatment of herpes simplex virus (HSV) infections (genital herpes, herpes labialis, herpes simplex encephalitis),Treatment of varicella-zoster virus (VZV) infections (chickenpox, herpes zoster),Neonatal herpes simplex virus infection,Off-label: Prevention of HSV reactivation in immunocompromised patients, treatment of eczema herpeticum
Intravenous infusion: Initial dose 5 mg/hour, titrate by 2.5 mg/hour every 5 minutes as needed to maximum 15 mg/hour. For maintenance, reduce to 3 mg/hour after blood pressure controlled. Label strength: 0.1 mg/m L in 0.86% Na Cl.
5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.
Terminal half-life 8.6 hours; in hepatic impairment, half-life may be prolonged up to 2-fold
Terminal elimination half-life in adults with normal renal function is 2.5-3.3 hours. In anuric patients, half-life extends to approximately 19.5 hours, necessitating dosage adjustment in renal impairment.
Hepatic via CYP3A4.
Acyclovir is partially metabolized by aldehyde oxidase and alcohol dehydrogenase to 9-carboxymethoxymethylguanine and other minor metabolites. The majority (62-90%) is excreted unchanged in urine via glomerular filtration and tubular secretion.
Renal (70-80% as metabolites, <1% unchanged), fecal (20-30%)
Primarily renal excretion via glomerular filtration and tubular secretion; approximately 62-91% of an administered dose is recovered unchanged in urine. Fecal excretion is minimal (<2%).
>95% bound to albumin and alpha-1-acid glycoprotein
9-33% bound to plasma proteins; binding is concentration-independent and predominantly to albumin.
0.3 L/kg; extensive tissue distribution consistent with high lipophilicity
Approximately 0.7 L/kg, indicating distribution into total body water. Penetrates well into tissues, including cerebrospinal fluid (CSF concentrations ~50% of plasma).
IV: 100% (not applicable for oral; oral bioavailability ~35% due to first-pass metabolism)
Intravenous administration yields 100% bioavailability. Oral bioavailability is 15-30% (not applicable to IV formulation).
No specific adjustment recommended for renal impairment; use caution.
Cr Cl >50 m L/min: no adjustment; Cr Cl 25-50 m L/min: 5-10 mg/kg every 12 hours; Cr Cl 10-25 m L/min: 5-10 mg/kg every 24 hours; Cr Cl <10 m L/min: 2.5-5 mg/kg every 24 hours; hemodialysis: give dose after dialysis.
Contraindicated in Child-Pugh Class C. Child-Pugh A-B: Reduce initial dose to 0.5 mg/hour and titrate slowly; maximum infusion rate 2 mg/hour.
No dose adjustment required for hepatic impairment; acyclovir is minimally metabolized by the liver.
Safety and efficacy not established; no standard dosing available.
Neonates (0-3 months): 10 mg/kg IV every 8 hours for HSV; Infants and children (3 months-12 years): 10 mg/kg IV every 8 hours for HSV, 20 mg/kg IV every 8 hours for VZV; maximum dose 500 mg/m² per dose.
Elderly patients: Start at lower end of dosing range (initial 3 mg/hour); titrate cautiously due to increased sensitivity and falls risk.
Elderly patients may have reduced renal function; adjust dose based on Cr Cl and monitor for neurotoxicity (e.g., confusion, hallucinations).
No FDA boxed warning exists for Cardene IV.
None.
May cause hypotension, especially in patients with reduced preload or on beta-blockers.,Use with caution in patients with congestive heart failure due to potential negative inotropic effects.,May increase angina frequency in patients with coronary artery disease.,Peripheral edema may occur.,Monitor blood pressure and heart rate closely during infusion.
Renal impairment: Dose adjustment required; monitor renal function.,Neurotoxicity: May cause agitation, hallucinations, confusion, seizures (especially in elderly or renally impaired).,Crystalluria: Risk increased with rapid infusion or dehydration; ensure adequate hydration.,Hemolytic uremic syndrome/thrombotic thrombocytopenic purpura (HUS/TTP): Rare but serious, reported in immunocompromised patients.,Pregnancy: Use only if clearly needed (Category B).
Known hypersensitivity to nicardipine or any component.,Advanced aortic stenosis (may reduce coronary perfusion).
Hypersensitivity to acyclovir, valacyclovir, or any component of the formulation.,Neonates: Use of bacteriostatic water-containing preparations (e.g., benzyl alcohol) is contraindicated.
No specific food interactions; maintain a low-sodium diet as recommended for hypertension. Avoid excessive grapefruit juice consumption as it may increase drug levels.
No specific food interactions. Adequate fluid intake is recommended to prevent renal toxicity. Avoid concurrent use of nephrotoxic substances (e.g., certain NSAIDs, aminoglycosides) without medical supervision.
First trimester: Limited data, no evidence of major malformations in animal studies. Second/third trimester: May cause fetal hypoxia, placental hypoperfusion, and intrauterine growth restriction due to maternal hypotension. Avoid in preeclampsia due to risk of fetal distress.
FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; use only if clearly needed.
Excreted in breast milk; M/P ratio not established. Use with caution; monitor infant for hypotension and bradycardia.
Acyclovir excreted in breast milk at low levels; M/P ratio unknown. Typical infant dose ~0.6 mg/kg/day (2-3% of maternal IV dose). No adverse effects reported in breastfeeding infants. Compatible with breastfeeding; caution with high maternal doses.
Increased plasma volume and clearance may require dose adjustment. Titrate to effect, starting with lower doses and monitoring blood pressure closely. No specific dose adjustment guidelines established.
Increased renal clearance and volume of distribution in pregnancy may reduce acyclovir exposure. No dose adjustment routinely recommended; however, higher doses or more frequent dosing may be considered for severe infections. Monitor therapeutic response.
Cardene IV (nicardipine) is a calcium channel blocker used for short-term treatment of hypertension when oral therapy is not feasible. Protect from light; do not use if discolored or contains precipitate. Titrate based on blood pressure response; monitor for hypotension, tachycardia, and peripheral edema. Use with caution in patients with heart failure, severe aortic stenosis, or impaired hepatic function. Administer via central line if peripheral IV access is limited due to phlebitis risk.
Acyclovir in sodium chloride 0.9% preservative-free is for IV administration only; do not administer IM or SC. Infuse over at least 1 hour to prevent renal tubular damage. Monitor renal function and adjust dose in renal impairment (Cr Cl <50 m L/min). Ensure adequate hydration (e.g., 500 m L IV fluids per gram acyclovir) to reduce risk of crystalluria. In obese patients, use ideal body weight for dosing. Phlebitis at infusion site is common; rotate sites.
This medication is given intravenously to lower blood pressure quickly.,Report any symptoms of low blood pressure such as dizziness, fainting, or excessive tiredness.,Notify your healthcare provider if you experience swelling in your ankles or feet, irregular heartbeat, or difficulty breathing.,Avoid pregnancy while on this medication; use effective contraception.,You may need frequent blood pressure monitoring during treatment.
This medication is given intravenously (into a vein) to treat viral infections.,Drink plenty of fluids before and during treatment to prevent kidney problems.,Report any pain, redness, or swelling at the injection site, or any lower back pain.,Tell your healthcare provider if you have kidney disease or are taking other medications that can affect the kidneys.,This drug does not cure herpes infections but helps reduce symptoms and recurrence.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Teriflunomide, the active metabolite of leflunomide, inhibits dihydroorotate dehydrogenase (DHODH), a key enzyme in de novo pyrimidine synthesis, exerting immunomodulatory effects. Acyclovir, an antiviral nucleoside analog, may inhibit organic anion transporter 3 (OAT3)-mediated renal tubular secretion of teriflunomide, leading to increased systemic exposure. Elevated teriflunomide concentrations can potentiate hepatotoxicity, myelosuppression, and immunosuppression, increasing the risk of infections and other adverse effects."
"The serum concentration of Acyclovir can be increased when it is combined with Tizanidine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER vs ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE, answered by our medical review team.
CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER is a Electrolyte that works by Cardene (nicardipine) is a dihydropyridine calcium channel blocker that inhibits the transmembrane influx of calcium ions into vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced afterload.. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is a Electrolyte that works by Acyclovir is a synthetic purine nucleoside analog with inhibitory activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2), and varicella-zoster virus (VZV). After intracellular conversion to acyclovir triphosphate, it inhibits viral DNA polymerase, leading to chain termination and viral DNA replication inhibition.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER is: Intravenous infusion: Initial dose 5 mg/hour, titrate by 2.5 mg/hour every 5 minutes as needed to maximum 15 mg/hour. For maintenance, reduce to 3 mg/hour after blood pressure controlled. Label strength: 0.1 mg/m L in 0.86% Na Cl.. The standard adult dose of ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is: 5 mg/kg IV every 8 hours (or 10 mg/kg IV every 8 hours for varicella-zoster or herpes simplex encephalitis) infused over 1 hour.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER and ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER is classified as Category A/B. First trimester: Limited data, no evidence of major malformations in animal studies. Second/third trimester: May cause fetal hypoxia, placental hypoperfusion, and intrauterine grow. ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE is classified as Category A/B. FDA Pregnancy Category B. No evidence of teratogenicity in animal studies. Limited human data: no increased risk of major birth defects or miscarriage. Risk cannot be ruled out; us. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.